The U.S. hemophilia treatment market, projected to reach a valuation of USD 4.48 Billion in 2025, is poised for steady growth. Estimates suggest the market will expand to USD 6.92 Billion by 2032, registering a CAGR of 6.4% during the forecast period. Current market dynamics highlight the increasing prevalence of hemophilia A and B, along with growing awareness and early diagnosis, as primary growth drivers. Advancements in recombinant therapies, extended half-life factor concentrates, and gene therapies are reshaping treatment paradigms. Additionally, rising healthcare expenditure, improved access to prophylactic treatment, and supportive reimbursement frameworks are further propelling market expansion across the U.S.

Key Takeaways

• By Product Type, recombinant coagulation factor segment is projected to dominate the market with a 38.1% share in 2025, attributed to their reduced risk of blood-borne pathogen transmission and increasing adoption in prophylactic hemophilia care.
• By Disease Type, hemophilia A is expected to lead the segment due to its higher prevalence compared to other types, accounting for the majority of diagnosed cases and treatment demand in the U.S.
• By Distribution Channel, hospital pharmacies are anticipated to hold the largest market share, driven by the administration of hemophilia therapies in controlled clinical settings and the preference for infusion-based treatments.
• Regionally, the Northeast emerges as the largest market, commanding over 40% of the U.S. pharmaceutical share, supported by advanced healthcare infrastructure, high awareness levels, and access to specialized treatment centers.

U.S. Hemophilia Treatment Market Report Coverage

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/us-hemophilia-treatment-market 

Report Coverage	Details
Market Revenue in 2025	USD 4.48 Billion
Estimated Value by 2032	USD 6.92 Billion
Growth Rate	Poised to exhibit a CAGR of 6.4%
Historical Data	2020-2024
Forecast Period	2025–2032
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	By Product Type, By Disease Type, and By Distribution Channel,
Geographies Covered	Northeast, West, South and Midwest
Growth Drivers	Rising Adoption of Prophylactic and Long-Acting Therapies Advancements in Genetic and Personalized Medicine
Trends	Shift Toward Subcutaneous and Non-Factor Therapies Emergence of Gene Therapy as a Long-Term Solution
Opportunities	Expansion of Home-Based Care and Specialty Pharmacy Services Integration of Digital Health and Remote Monitoring Platforms
Restraints & Challenges	High Cost of Advanced Therapies Limited Access to Specialized Treatment Centers

Market Dynamics

The U.S. hemophilia treatment market is experiencing steady growth, fueled by the increasing prevalence of hemophilia A and B, rising awareness, and improvements in diagnostic accuracy and early screening. The adoption of prophylactic treatment regimens and the shift from plasma-derived to recombinant coagulation factors are reshaping the therapeutic landscape, offering enhanced safety and efficacy. The growing focus on personalized care, combined with advancements in extended half-life factor concentrates and non-factor therapies, is improving patient compliance and clinical outcomes.

In June 2023, the FDA approved Roctavian (valoctocogene roxaparvovec), the first gene therapy for adults with severe hemophilia A, as a one-time infusion. Clinical data from the Phase 3 GENEr8-1 trial demonstrated reductions in annualized bleeding rates and factor VIII usage by 82.9% and 96.8%, respectively, over three years.

Furthermore, market dynamics are positively influenced by favorable reimbursement policies, expanding access to specialty treatment centers, and growing investment in R&D by biopharmaceutical firms. Strategic collaborations between drug manufacturers and advocacy organizations are also helping to address unmet patient needs and improve access to care. As innovation in gene therapy, subcutaneous delivery platforms, and extended-release formulations continues to gain momentum, the U.S. hemophilia treatment market is positioned for sustained expansion through 2032.

Market Trends

• Growing Preference for Subcutaneous and Non-Factor Therapies

The U.S. hemophilia treatment landscape is witnessing a significant shift toward subcutaneous and non-factor therapies, driven by the demand for more convenient and less frequent dosing regimens. These therapies offer an alternative to traditional intravenous factor replacement, improving adherence and quality of life for patients with hemophilia A and B, including those with inhibitors.

In March 2025, Sanofi launched Qfitlia (fitusiran), a bi-monthly subcutaneous siRNA therapy approved for hemophilia A and B patients aged 12 and older. Clinical trials demonstrated a 71–90% reduction in annualized bleeding rates compared to on-demand treatment, establishing Qfitlia as a transformative option for long-term prophylaxis in the U.S. market.

• Emergence of Hemostasis-Modulating Agents in the Pipeline

The U.S. hemophilia treatment market is witnessing growing interest in hemostasis-modulating agents that work independently of factor replacement. These novel therapies aim to rebalance coagulation pathways and offer effective bleed control with convenient dosing and broad patient applicability, including those with inhibitors.

In December 2023, Pfizer presented data at the American Society of Hematology, where marstacimab (an anti-TFPI monoclonal antibody) achieved a 35% reduction in annualized bleeding rates vs. standard prophylaxis—and 92% vs. on-demand therapy—in hemophilia A and B patients without inhibitors.

Market Opportunities

• Integration of Digital Health and Remote Monitoring Solutions

The rise of digital platforms in chronic disease management presents a compelling opportunity for remote monitoring of hemophilia patients. Wearable devices and mobile health apps can help track bleeding episodes, treatment adherence, and infusion logs—reducing emergency visits and enabling data-driven, personalized care.

In January 2025, Pfizer partnered with Huma to roll out an FDA-cleared remote patient monitoring (RPM) platform across U.S. hemophilia centers. The system combines a patient app and clinician portal to log symptoms, vitals, bleeding episodes, and infusions, with tailored nurse navigator support—enhancing adherence, engagement, and timely clinical intervention.

• Growth in Specialty Pharmacies and Home Infusion Services

With an increasing number of hemophilia patients shifting toward at-home care, specialty pharmacies and home infusion providers are becoming critical enablers of decentralized treatment. These providers support patient adherence through comprehensive services, including cold-chain delivery, nurse-assisted administration, insurance coordination, and remote education. As demand rises for extended half-life therapies and subcutaneous options, companies with robust home-care logistics and patient engagement platforms are well-positioned to gain market share.

In August 2024, CarePartners Pharmacy completed the acquisition of Evolutionary Pharmacy Solutions (EPSRx), expanding its specialty infusion network across 36 U.S. states. The acquisition bolstered CarePartners’ ability to deliver high-touch, at-home IV infusion services for chronic conditions, including hemophilia, underscoring a strategic push to scale home-based care infrastructure tailored to complex therapies.

Analyst View

• The U.S. hemophilia treatment market is evolving rapidly, marked by the growing adoption of innovative therapies and a shift toward more personalized, patient-centric care. Extended half-life factor concentrates, subcutaneous therapies, and gene-based treatments are transforming traditional treatment paradigms by improving convenience, reducing treatment frequency, and enhancing long-term outcomes. The recent approvals of one-time gene therapies and non-factor therapies signal a major inflection point in the market’s development.
• Digital health integration and the expansion of home-based care models are further strengthening the ecosystem. Remote monitoring platforms, wearable technologies, and specialty pharmacies offering cold-chain logistics and nurse-assisted infusions are enhancing patient adherence, reducing hospital visits, and supporting decentralized treatment. These developments are particularly significant as patients and providers seek more flexible, high-quality care delivery outside of traditional clinical settings.
• In parallel, continued investment in R&D and supportive reimbursement frameworks are reinforcing innovation and access across the care continuum. With strong momentum in pipeline development—especially for hemostasis-modulating agents and rebalancing therapies—the market is positioned for sustained advancement. Stakeholders that align with emerging treatment preferences, digital transformation, and integrated care delivery models are expected to thrive in this dynamic landscape.

Key Developments

• In May 2023, Pfizer Inc. announced that the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab has met its primary endpoints, having demonstrated statistically significant and clinically meaningful effects. Marstacimab, a novel, investigational anti-tissue factor pathway inhibitor (anti-TFPI) being studied for the treatment of hemophilia A or B for people without inhibitors to Factor VIII (FVIII) or Factor IX (FIX), was administered weekly with flat (not weight-based) dosing in the trial as a subcutaneous 300 mg loading dose followed by 150 mg once weekly.
• In April 2023, Two studies, published in The Lancet and The Lancet Haematology, evaluating the efficacy and safety of fitusiran, an investigational siRNA therapy for the prophylactic treatment of adults and adolescents with hemophilia A or B, reinforce the potential of this investigational therapy to transform the current standard of care and address unmet needs for all types of hemophilia, regardless of inhibitor status.

Competitors Landscape

• Takeda Pharmaceutical Company Limited.
• Sanofi Octapharma AG
• Swedish Orphan Biovitrum AB
• Baxter International Inc.
• Biogen Inc.
• Bayer AG
• CSL Behring
• Ferring B.V.
• Pfizer, Inc.
• Kedrion
• Novo Nordisk A/S
• Grifols S.A.
• Sangamo Therapeutics, Inc.,
• Spark Therapeutics, Inc.

U.S. Hemophilia Treatment Market Segmentation

• By Product Type
• Recombinant Coagulation Factor
• Plasma Derived Coagulation Factor
• Antifibrinolytic Agents
• Others
• By Disease Type
• Hemophilia A
• Hemophilia B
• Hemophilia C
• By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Geography
• Northeast
• West
• South
• Midwest